| Project/Area Number |
15K18931
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | リポソーム / EGCG / ラミニンレセプター / 抗腫瘍効果 |
|---|
| Outline of Final Research Achievements |
We studied usability of (-)-epigallocatechin-3-gallate and polyethyleneglycol modified liposomal doxorubicin (EPL) for increase antitumor effect against high grade tumor cell with 67 kDa laminin receptor (67LR). EGCG-monoamine, novel EGCG-derivative was synthesized, was used as modified molecular on liposomal membrane. When tumor bearing mice which was subcutaneously planted on B16F10 mouse melanoma cells was administered EPL, antitumor effect of EPL was stronger than that of PEG modified liposomal doxorubicin (PL). Moreover, EPL became activated caspase-3 in tumor, namely it induced apoptosis by binding 67LR on tumor cells. In conclusion, it was expected that EPL was superior formulation for cancer treatment.
|
